stoxline Quote Chart Rank Option Currency Glossary
  
Kintara Therapeutics, Inc. (KTRA)
0.104  0.015 (16.2%)    03-28 16:00
Open: 0.1013
High: 0.1075
Volume: 31,453,911
  
Pre. Close: 0.0895
Low: 0.1004
Market Cap: 4(M)
Technical analysis
2024-03-28 4:52:35 PM
Short term     
Mid term     
Targets 6-month :  0.13 1-year :  0.15
Resists First :  0.11 Second :  0.13
Pivot price 0.09
Supports First :  0.08 Second :  0.06
MAs MA(5) :  0.09 MA(20) :  0.09
MA(100) :  0.18 MA(250) :  2.28
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  25.3 D(3) :  19.5
RSI RSI(14): 51.8
52-week High :  5.98 Low :  0.08
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ KTRA ] has closed below upper band by 20.9%. Bollinger Bands are 95.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.11 - 0.11 0.11 - 0.11
Low: 0.1 - 0.1 0.1 - 0.1
Close: 0.1 - 0.1 0.1 - 0.11
Company Description

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Headline News

Thu, 28 Mar 2024
KTRA Stock Quote Price and Forecast - CNN

Wed, 27 Mar 2024
Kintara Therapeutics expands REM-001 study to include patients on pembrolizumab - Seeking Alpha

Wed, 27 Mar 2024
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab - PR Newswire

Thu, 22 Feb 2024
Kintara Therapeutics Halts ATM Offerings and Equity Facility Usage - TipRanks.com - TipRanks

Wed, 14 Feb 2024
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update - PR Newswire

Tue, 02 Jan 2024
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ: - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 39 (M)
Shares Float 39 (M)
Held by Insiders 0.2 (%)
Held by Institutions 0.6 (%)
Shares Short 2,190 (K)
Shares Short P.Month 164 (K)
Stock Financials
EPS -5.22
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.02
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -112.7 %
Return on Equity (ttm) -329 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.28
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.02
PEG Ratio 0
Price to Book value -0.11
Price to Sales 0
Price to Cash Flow -0.6
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android